Therapeutic Decision-Making in the Adjuvant Setting in HR+ Breast Cancer

Goals and standards of care for therapy in patients with early-stage HR-positive breast cancer.

Considerations for therapeutic decision-making in adjuvant and neoadjuvant settings in early-stage HR-positive breast cancer.

The role of gene profiling assays in identifying candidates for chemotherapy in early HR-positive breast cancer.

Results of 2 prospective, randomized clinical trials of the Oncotype DX Breast Recurrence Score and implications for practice.

Considerations for using gene profiling assays to identify appropriate patients for neoadjuvant therapy in early-stage HR-positive breast cancer.

Debu Tripathy, MD, of the University of Texas MD Anderson Cancer Center, comments on current NCCN recommendations for the use of prognostic and predictive gene profiling assays to individualize treatment in patients with HR-positive breast cancer.

Kevin Kalinsky, MD, MS, of Emory Winship Cancer Institute, discusses treatment options for HR-positive/HER2-negative breast cancer and comments on the evolving role of genomic testing in regard to treatment selection.

Dr Kevin Kalinsky describes when and for whom neoadjuvant therapy may be appropriate for the management of HR-positive breast cancer.

The value of utilizing a genomic test to help guide decisions for adjuvant therapy for HR-positive breast cancer.

A discussion on the types of information provided by genetic tests and genomic assays and recommendations for use in HR-positive breast cancer.

Implications for using the Oncotype DX Breast Recurrence Score to help tailor therapy for patients with HR-positive, HER2-negative breast cancer based on data demonstrated in the TAILORx and RxPONDER studies.